Immunovia Sets Exercise Price for Warrant Series TO 3

Immunovia AB, a pioneering diagnostics company based in Lund, Sweden, has officially announced the exercise price for its warrant series TO 3. The determined exercise price is SEK 0.24 per warrant, and it will be effective from April 1, 2025, until April 15, 2025. The critical trading period for these warrants will conclude on April 11, 2025, allowing investors ample time to make informed decisions.

Background on the Rights Issue

In a significant move last year, Immunovia executed a rights issue of units from August to September 2024. Each unit consisted of two shares, two series TO 2 warrants, and one TO 3 warrant. This series of warrants gives the holder the right to subscribe for one new share in the company. If all warrants are exercised, Immunovia anticipates raising around SEK 14.9 million before any associated costs.

The subscription price is based on 70% of the volume-weighted average price of Immunovia's stock on the Nasdaq Stockholm, taking into account the period from March 14 to March 27, 2025. This calculated average price amounted to approximately SEK 0.24 per share, thereby setting the subscription price at SEK 0.24 per share.

Key Dates for Investors

Here are the important dates concerning the warrants:

- Exercise Period: April 1, 2025 - April 15, 2025
- Last Trading Day: April 11, 2025
- Expiry of Unexercised Warrants: April 15, 2025

Warrants not exercised before the expiry date will have no value. Investors who prefer not to exercise their warrants can opt to sell them on the Nasdaq Stockholm until the specified date.

Instructions for Exercising Warrants

Investors holding nominee-registered warrants must notify their nominees to initiate the exercise process, following the required steps laid out by the nominee. This process should begin ahead of the final date to ensure smooth transaction completion, as different nominees may have varied processing times.

For directly registered warrants, holders must fill out and submit a dedicated application form to Vator Securities AB, the issuing agent for these warrants, ensuring that this application reaches them no later than April 15, 2025. Detailed instructions can be found on both Immunovia's and Vator Securities’ official websites.

Potential Impact on Share Capital

If all 62,211,989 TO 3 warrants are exercised, Immunovia's share capital would witness an increase of up to SEK 1,866,359.67, bringing the total to SEK 9,723,625.56. Following this, the total number of shares in the company would rise from 261,908,863 to 324,120,852. Notably, this exercise would result in a dilution effect of approximately 19.2% for existing shareholders.

Conclusion

As Immunovia aims to enhance survival rates for pancreatic cancer patients through advanced diagnostic methods, the execution of these warrants is a strategic step toward securing necessary funding. Investors are encouraged to seek further information on the company's official website and stay informed about upcoming developments and regulatory aspects affecting the exercise of these warrants.

For additional inquiries, investors may contact Immunovia's CEO, Jeff Borcherding. The complete terms and conditions regarding the warrants can also be found on Immunovia's website.

With innovative approaches to diagnostics, Immunovia continues to solidify its position in the healthcare landscape, particularly focusing on detecting high-risk individuals for pancreatic cancer—addressing a critical need in early detection.

For detailed information, visit: Immunovia